Clin2
NCT05985655Possibly a fitRecruiting

Study of GTAEXS617 for advanced solid tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast CarcinomaTriple Negative Breast Cancer (TNBC)

Part of Cancer, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
230 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are generally able to take care of yourself (ECOG score 0 or 1).
  • Your doctor expects you to live more than 3 months.
  • You have one of these cancers: head and neck, pancreatic, non-small cell lung, certain breast cancers, or ovarian/fallopian tube cancers that have not responded to standard therapy.
  • Your cancer is advanced, has come back, or has spread, and surgery or radiation is not likely to cure it.
  • You have at least one tumor that can safely be biopsied (not in the bone).
  • Your blood counts, liver, and kidney function are adequate.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07517198Recruiting· Phase 1
EXS74539 Study for Advanced Solid Tumors

This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.

Los Angeles, California
NCT06476808Recruiting· Phase 1
Testing a new drug for advanced solid tumors

This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.

Los Angeles, California
NCT06927570Recruiting· Phase 1
Study of HS-20122 for advanced solid tumors

This trial tests a new drug called HS-20122 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.

Guangzhou, Guangdong
NCT06551142Recruiting· Phase 1
Study of GSK5764227 for advanced solid tumors

This study tests a new drug called GSK5764227 for people with advanced solid tumors. It aims to see if the drug is safe and works against cancer that has stopped responding to other treatments.

Stanford, California
NCT07032298Recruiting· Phase 1
Testing SSGJ-612 for advanced solid tumors with HER2

This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.

Luoyang, Henan
NCT07438782Recruiting· Phase 1
Study of a new drug for advanced solid tumors

This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.

Philadelphia, Pennsylvania

Hear when a new Pancreatic Adenocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.